MNG554
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.366
- MYC_TARGETS_V1+0.350
- PROTEIN_SECRETION+0.335
- OXIDATIVE_PHOSPHORYLATION+0.315
- ANDROGEN_RESPONSE+0.276
- CHOLESTEROL_HOMEOSTASIS+0.233
- PEROXISOME+0.223
- INTERFERON_GAMMA_RESPONSE+0.211
- TGF_BETA_SIGNALING+0.204
- GLYCOLYSIS+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.445
- IL6_JAK_STAT3_SIGNALING-0.275
- APICAL_SURFACE-0.208
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.199
- IL2_STAT5_SIGNALING-0.181
- INFLAMMATORY_RESPONSE-0.144
- KRAS_SIGNALING_UP-0.144
- MYOGENESIS-0.125
- E2F_TARGETS-0.046
- G2M_CHECKPOINT-0.042
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG747 | — | — | 0.751 |
| 2 | TCGA-C8-A26V-01A-11R-A16F-07 | — | B | 0.677 |
| 3 | 713c3ad2-c1d0-45ed-b69e-f6cedd57933a | — | — | 0.666 |
| 4 | TCGA-CV-5439-01A-01R-1686-07 | — | — | 0.647 |
| 5 | SRR6013523 | — | cohortA1 | 0.643 |
| 6 | TCGA-CV-A6K2-01A-11R-A31N-07 | — | — | 0.635 |
| 7 | MNG949 | — | — | 0.632 |
| 8 | TCGA-B6-A0WW-01A-11R-A109-07 | — | B | 0.619 |
| 9 | SRR1313114 | — | B | 0.608 |
| 10 | SRR23303763 | — | — | 0.607 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.366 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.335 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.315 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.276 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.233 | Remibrutinib | — uncovered |
| PEROXISOME | 0.223 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.211 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.204 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.182 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.179 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.164 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.164 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.158 | Inavolisib | — uncovered |
| HYPOXIA | 0.142 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.138 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.137 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.118 | Idelalisib | — uncovered |
| COMPLEMENT | 0.117 | Inavolisib | — uncovered |